Male Breast Cancer
Table of Contents
What is male breast cancer?
Male Breast Cancer
Source: National Cancer Institute (NCI)
Male breast cancer is a disease in which malignant (cancer) cells form in the tissues of the breast.
Breast cancer may occur in men. Breast cancer may occur in men at any age, but it usually occurs in men between 60 and 70 years of age. Male breast cancer makes up less than 1% of all cases of breast cancer.
The following types of breast cancer are found in men:
Infiltrating ductal carcinoma: Cancer that has spread beyond the cells lining ducts in the breast. This is the most common type of breast cancer in men.
Ductal carcinoma in situ: Abnormal cells that are found in the lining of a duct; also called intraductal carcinoma.
Inflammatory breast cancer: A type of cancer in which the breast looks red and swollen and feels warm.
Paget disease of the nipple: A tumor that has grown from ducts beneath the nipple onto the surface of the nipple.
Lobular carcinoma in situ (abnormal cells found in one of the lobes or sections of the breast), which sometimes occurs in women, has not been seen in men.
How is male breast cancer treated?
The National Cancer Institute’s PDQ Cancer Information Summary about breast cancer and pregnancy includes the following :
Surgery
Surgery for men with breast cancer is usually a modified radical mastectomy, surgery to remove the whole breast that has cancer. This may include removal of the nipple, areola (the dark-colored skin around the nipple), and skin over the breast. Most of the lymph nodes under the arm are also removed.
Breast-conserving surgery, an operation to remove the cancer but not the breast itself, is also used for some men with breast cancer. A lumpectomy is done to remove the tumor (lump) and a small amount of normal tissue around it. Radiation therapy is given after surgery to kill any cancer cells that are left.
Chemotherapy
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).
Hormone therapy
Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops cancer cells from growing. Hormones are substances made by glands in the body and circulated in the bloodstream. Some hormones can cause certain cancers to grow. If tests show that the cancer cells have places where hormones can attach (receptors), drugs, surgery, or radiation therapy is used to reduce the production of hormones or block them from working.
Hormone therapy with tamoxifen is often given to patients with estrogen-receptor and progesterone-receptor positive breast cancer and to patients with metastatic breast cancer (cancer that has spread to other parts of the body).
Hormone therapy with an aromatase inhibitor is given to some men who have metastatic breast cancer. Aromatase inhibitors decrease the body’s estrogen by blocking an enzyme called aromatase from turning androgen into estrogen. Anastrozole, letrozole, and exemestane are types of aromatase inhibitors.
Hormone therapy with a luteinizing hormone-releasing hormone (LHRH) agonist is given to some men who have metastatic breast cancer. LHRH agonists affect the pituitary gland, which controls how much testosterone is made by the testicles. In men who are taking LHRH agonists, the pituitary gland tells the testicles to make less testosterone. Leuprolide and goserelin are types of LHRH agonists.
Other types of hormone therapy include megestrol acetate or anti-estrogen therapy, such as fulvestrant.
Radiation therapy
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Targeted therapy
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Monoclonal antibody therapy, tyrosine kinase inhibitors, cyclin-dependent kinase inhibitors, and mammalian target of rapamycin (mTOR) inhibitors are types of targeted therapies used to treat men with breast cancer.
Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.
Types of monoclonal antibody therapy include the following:
Trastuzumab is a monoclonal antibody that blocks the effects of the growth factor protein HER2.
Pertuzumab is a monoclonal antibody that may be combined with trastuzumab and chemotherapy to treat breast cancer.
Ado-trastuzumab emtansine is a monoclonal antibody linked to an anticancer drug. This is called an antibody-drug conjugate. It may be used to treat men with hormone receptor positive breast cancer that has spread to other parts of the body. https://www.youtube-nocookie.com/embed/dxnjAc-rqz8?rel=0
Tyrosine kinase inhibitors are targeted therapy drugs that block signals needed for tumors to grow. Lapatinib is a tyrosine kinase inhibitor that may be used to treat men with metastatic breast cancer.
Cyclin-dependent kinase inhibitors are targeted therapy drugs that block proteins called cyclin-dependent kinases, which cause the growth of cancer cells. Palbociclib is a cyclin-dependent kinase inhibitor used to treat men with metastatic breast cancer.
Mammalian target of rapamycin (mTOR) inhibitors block a protein called mTOR, which may keep cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow.
See full article at National Cancer Institute
Updated September 2024